Apogee Therapeutics (APGE) AI Stock Analysis

• Market Cap: $2.36B
• Dividend Yield: N/A
• Average Volume (3M): 731.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: N/A
• EPS Growth: -94.92%
• Country: US
• Employees: 196
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -3.23
• Shares Outstanding: 46,016,540
• 10 Day Avg. Volume: 673,137
• 30 Day Avg. Volume: 731,792
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -8.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $94.43
• Price Target Upside: 152.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Apogee Therapeutics is in a challenging financial position typical of early-stage biotech firms, with no revenues and high cash burn. However, the stock has potential upside due to promising clinical trial results and a strong cash position. Despite current bearish technicals and valuation concerns, these factors could offer future growth opportunities if clinical advancements continue to materialize.

Positive Factors

Clinical Trials

Apogee once again exceeded expectations with the impressive Phase I APG990 data.

Management Performance

This management team has done nothing but exceed expectations and execute on all fronts, potentially enabling Apogee to become a generational biotech and generate tens of billions of dollars of value.

Market Potential

APG777 monotherapy has the potential to reach $10B+ of peak sales alone.

Negative Factors

Financial Performance

APGE reported a wider net loss in FY2024 ($182.1M vs $84.0M in FY2023) due to increased R&D investment.

Apogee Therapeutics Business Overview & Revenue Model

Company Description

Apogee Therapeutics (APGE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for immunological and inflammatory diseases. The company leverages advanced scientific research and technologies to address unmet medical needs in these areas, aiming to improve patient outcomes with their novel drug candidates.

How the Company Makes Money

Apogee Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the successful development and commercialization of its therapies. Additionally, Apogee may earn revenue from selling its developed therapeutics once they receive regulatory approval and are brought to market.

Apogee Therapeutics Financial Statement Overview

Summary

Apogee Therapeutics exhibits financial characteristics typical of an early-stage biotechnology firm. The company has zero revenue and increasing operational expenses, resulting in profitability challenges. It relies heavily on equity financing, maintaining a strong cash position, but faces risks from high cash burn and negative free cash flow.

Income Statement

Apogee Therapeutics has reported zero revenue over the past three years, which is typical for early-stage biotechnology firms focusing on research and development. The company’s EBIT and EBITDA have significantly worsened, reflecting increased operational expenses without revenue offset. The absence of revenue growth and negative net income margins highlight substantial profitability challenges.

Balance Sheet

The balance sheet shows a strong equity position with a substantial increase in stockholders’ equity, driven by financing activities likely tied to capital raises. The debt-to-equity ratio remains low, indicating minimal leverage. However, total assets are primarily composed of cash and equivalents, which could indicate a lack of diversification in asset allocation.

Cash Flow

The company’s cash flow statement shows significant reliance on financing activities to fund operations, typical for biotech companies in the development phase. Operating cash flow is negative, consistent with its stage, but free cash flow has deteriorated, indicating increasing cash burn rates. This trend could pose liquidity risks if external funding becomes challenging.

Breakdown
Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00
	EBIT
-216.87M	-93.00M	-30.73M
	EBITDA
-216.87M	-83.98M	0.00
	Net Income Common Stockholders
0.00	-83.98M	-39.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
520.65M	395.46M	151.89M
	Total Assets
753.95M	401.40M	152.06M
	Total Debt
11.83M	2.03M	0.00
	Net Debt
-129.96M	-116.28M	-151.89M
	Total Liabilities
37.16M	21.49M	9.98M
	Stockholders Equity
716.79M	379.91M	-39.78M
Cash Flow		Free Cash Flow
-172.33M	-74.93M	-16.43M
	Operating Cash Flow
-171.17M	-74.76M	-16.43M
	Investing Cash Flow
-300.46M	-273.91M	0.00
	Financing Cash Flow
495.11M	315.39M	183.62K

Apogee Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 37.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Negative. The current price of 37.36 is below the 20-day moving average (MA) of 38.51, below the 50-day MA of 37.56, and below the 200-day MA of 45.58, indicating a bearish trend. The MACD of 0.38 indicates Positive momentum. The RSI at 41.65 is Neutral, neither overbought nor oversold. The STOCH value of 32.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APGE.

Apogee Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$69.68B	16.63	15.95%	0.14%	8.27%	10.35%
NBIX	68 Neutral	$11.28B	33.61	14.16%	―	24.81%	33.67%
BIIB	65 Neutral	$20.25B	12.37	10.36%	―	-1.60%	39.71%
VRTX	64 Neutral	$126.52B	―	-3.15%	―	11.64%	-114.72%
ALNY	55 Neutral	$34.92B	―	-414.62%	―	22.97%	38.54%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
APGE	41 Neutral	$2.36B	―	-33.22%	―	―	-94.92%

Apogee Therapeutics Corporate Events

Apogee Therapeutics Reports Positive Phase 1 Results

On March 3, 2025, Apogee Therapeutics announced positive interim Phase 1 results from its first-in-human trial of APG990, which exceeded trial objectives and demonstrated potential for extended dosing intervals. The company also reported significant progress in its pipeline, including the accelerated execution of the Phase 2 APEX clinical trial for APG777 and plans for further trials in asthma and eosinophilic esophagitis. Apogee’s strong financial position, with $731.1 million in cash and marketable securities, supports its operations into 2028, despite increased R&D and G&A expenses in 2024.

Apogee Therapeutics Advances APG777 in Key Phase 2 Trial

On February 3, 2025, Apogee Therapeutics announced the dosing of the first patient in the Part B portion of their Phase 2 APEX clinical trial for APG777, targeting patients with moderate-to-severe atopic dermatitis. The trial combines Phase 2a and 2b protocols, with Part A seeing an exceeded enrollment of 123 patients, and Part B involving approximately 280 patients. This advancement underscores APG777’s potential in providing effective treatment options with reduced injection burdens and improved disease control, positioning Apogee as a competitive player in the I&I markets.